Where Will Celldex Therapeutics, Inc. (CLDX) Stock Go Next After It Is Up 23.13% in a Week?

Tuesday, September 29, 2020 3:20 PM | InvestorsObserver Analysts

Celldex Therapeutics, Inc. (CLDX) stock has gained 23.13% over the past week and gets a Bullish rating from InvestorsObserver's Sentiment Indicator.

Sentiment Score - ,bullish
Celldex Therapeutics, Inc. has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CLDX!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.

As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.

Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.

InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.

The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With CLDX Stock Today?

Celldex Therapeutics, Inc. (CLDX) stock is trading at $15.33 as of 3:17 PM on Tuesday, Sep 29, a rise of $0.35, or 2.34% from the previous closing price of $14.98. Volume today is more active than usual. So far 1,877,707 shares have traded compared to average volume of 723,557 shares. The stock has traded between $14.22 and $16.19 so far today.

To screen for more stocks like Celldex Therapeutics, Inc. click here.

More About Celldex Therapeutics, Inc.

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140, and CDX-3379.

Click Here to get the full Stock Score Report on Celldex Therapeutics, Inc. (CLDX) Stock.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like